Abstract: Tocol derivative compounds, compositions comprising these tocol derivatives and methods of using the tocol derivatives are provided herein. Specifically the tocol derivatives have a partially unsaturated hydrocarbon tail and are thus distinct from the tocopherols. The hydrocarbon tails do not have a trans carbon-carbon double bond in the second isoprene unit of the hydrocarbon tail and are distinct from the tocotrienols. The compounds are expected to allow improved interaction with the a-tocopherol transfer protein receptor than the tocotrienols and better bioactivity than the tocopherols.

Abstract: Provided herein is a tocol rich fraction of rice bran oil deodorized distillate that is shown to be both radioprotective and able to protect against oxidative damage. This fraction may prove an inexpensive and readily available extract that can be used to prepare pharmaceutical compositions for use in protecting against radiation exposure and/or other forms of oxidative stress.

Abstract: Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise ?-tocotrienol (GT3) and ?-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.

Abstract: Provided herein is a tocol rich fraction of rice bran oil deodorized distillate that is shown to be both radioprotective and able to protect against oxidative damage. This fraction may prove an inexpensive and readily available extract that can be used to prepare pharmaceutical compositions for use in protecting against radiation exposure and/or other forms of oxidative stress.

Abstract: Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise ?-tocotrienol (GT3) and ?-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.

Abstract: Tocol derivative compounds, compositions comprising these tocol derivatives and methods of using the tocol derivatives are provided herein. Specifically the tocol derivatives have a partially unsaturated hydrocarbon tail and are thus distinct from the tocopherols. The hydrocarbon tails do not have a trans carbon-carbon double bond in the second isoprene unit of the hydrocarbon tail and are distinct from the tocotrienols. The compounds are expected to allow improved interaction with the ?-tocopherol transfer protein receptor than the tocotrienols and better bioactivity than the tocopherols.

Abstract: Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise ?-tocotrienol (GT3) and ?-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.

Abstract: Provided herein is a tocol rich fraction of rice bran oil deodorized distillate that is shown to be both radioprotective and able to protect against oxidative damage. This fraction may prove an inexpensive and readily available extract that can be used to prepare pharmaceutical compositions for use in protecting against radiation exposure and/or other forms of oxidative stress.

Abstract: Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise ?-tocotrienol (GT3) and ?-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.

Abstract: Methods for the synthesis of tocoflexols of Formula (I) and (II) and a number of related tocol analogs are provided herein. The methods are economical and amenable to large scale production and can be performed using either pure of partially purified tocotrienols as the starting material.

Abstract: Methods for the synthesis of tocoflexols of Formula (I) and (II) and a number of related tocol analogues are provided herein. The methods are economical and amenable to large scale production and can be performed using either pure of partially purified tocotrienols as the starting material.

Abstract: Tocol derivative compounds, compositions comprising these tocol derivatives and methods of using the tocol derivatives are provided herein. Specifically the tocol derivatives have a partially unsaturated hydrocarbon tail and are thus distinct from the tocopherols. The hydrocarbon tails do not have a trans carbon-carbon double bond in the second isoprene unit of the hydrocarbon tail and are distinct from the tocotrienols. The compounds are expected to allow improved interaction with the ?-tocopherol transfer protein receptor than the tocotrienols and better bioactivity than the tocopherols.

Abstract: The invention relates to the field of radiation injury. More particularly, this invention relates to the protection against/prevention of and treatment of diseases caused by ionizing radiation by the use of thrombomodulin.

Abstract: The present invention relates to methods useful for treating and/or preventing radiation- and/or chemical-induced toxicity in non-malignant tissue using a protease activated receptor-1 (PAR-1) inhibitor. In particular, use of a protease activated receptor-1 (PAR-1) inhibitor to treat and/or prevent acute and chronic adverse effects of radiation and/or chemical exposure (e.g., to one or more of the following: intestine, lung, oral mucosa, or other organs).

Abstract: Intestinal radiation injury (radiation enteropathy) is an important dose limiting factor during treatment of abdominal and pelvic tumors and a major determinant in the quality of life among cancer survivors. Inflammatory and fibrogenic mediators released by mucosal inflammatory cells are involved in the mechanisms of injury. Treatment with Orazipone decreases the toxicity following Gy radiation dose, as measured by histopathologic scoring, TGF-&bgr;, IL-1&agr;, and ED-2 macrophage antigen immunoreactivity.